Initially, these medications were believed to abort migraines by targeting the vasoconstricting 5-HT1 receptors solely in the cerebral vasculature.1 Coronary circulation was believed to possess only serotonin 5-HT2 receptors, ensuring that coronary vasoconstriction would be avoided in triptan use. Here, HTR2A is linked to migraine disorder.